In summary, the development of mRNA electroporated moDCs simplified anti-cancer immunotherapy significantly as transfection of DCs not only induces a broad, HLA-independent CD4+ and CD8+ immune response but also reduces the time and costs for vaccine preparation. Here, CD8A is linked to cancer.